Biotech Values

[DewDiligence]

Sanofi Reports 3Q09 Annualized Lovenox Sales of $4.4B

[Sanofi’s reporting currency is the Euro, but the growth rates reported below are in local currencies unless otherwise specified. Tallying growth in local currencies is a way to track the change in volume and price irrespective of exchange rates. The figures below are annualized, i.e. they are 4x the reported 3Q09 numbers.]


Worldwide Lovenox sales rose 14% year-over-year (18% in Euros) to an annualized rate of €3.0B, which is $4.4B at the current exchange rate.

In the US (where MNTA and NVS have filed an application to sell generic Lovenox), annualized 3Q09 Lovenox sales rose 8% in dollars to $2.6B.

The breakdown of 3Q09 sales by geography is as follows (growth rates are year-over-year in local currencies):

US: €1.77B (59% of total), 8% growth
EU: €880M (29% of total), 23% growth
RoW: €330M (11% of total), 19% growth
===
Total: €2.99B, 14% growth

Source: http://en.sanofi-aventis.com/binaries/20091030_results_q3_2009_en_tcm28-26643.pdf